Novavax rises on publication of data from A(H7N9) vaccine candidate study

Novavax (NVAX) jumps 9% premarket.

Wednesday evening, the company announced that The New England Journal of Medicine published what NVAX calls "positive clinical data" from a study of  the VLP A(H7N9) vaccine candidate.

Summary: The vaccine was well tolerated, safety was "in-line with previous findings," and 81% and 97% of 5ug adjuvanted vaccine recipients had protective HAI levels and anti-neuraminidase antibody responses, respectively. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs